AGL 38.48 Decreased By ▼ -0.08 (-0.21%)
AIRLINK 203.02 Decreased By ▼ -4.75 (-2.29%)
BOP 10.17 Increased By ▲ 0.11 (1.09%)
CNERGY 6.54 Decreased By ▼ -0.54 (-7.63%)
DCL 9.58 Decreased By ▼ -0.41 (-4.1%)
DFML 40.02 Decreased By ▼ -1.12 (-2.72%)
DGKC 98.08 Decreased By ▼ -5.38 (-5.2%)
FCCL 34.96 Decreased By ▼ -1.39 (-3.82%)
FFBL 86.43 Decreased By ▼ -5.16 (-5.63%)
FFL 13.90 Decreased By ▼ -0.70 (-4.79%)
HUBC 131.57 Decreased By ▼ -7.86 (-5.64%)
HUMNL 14.02 Decreased By ▼ -0.08 (-0.57%)
KEL 5.61 Decreased By ▼ -0.36 (-6.03%)
KOSM 7.27 Decreased By ▼ -0.59 (-7.51%)
MLCF 45.59 Decreased By ▼ -1.69 (-3.57%)
NBP 66.38 Decreased By ▼ -7.38 (-10.01%)
OGDC 220.76 Decreased By ▼ -1.90 (-0.85%)
PAEL 38.48 Increased By ▲ 0.37 (0.97%)
PIBTL 8.91 Decreased By ▼ -0.36 (-3.88%)
PPL 197.88 Decreased By ▼ -7.97 (-3.87%)
PRL 39.03 Decreased By ▼ -0.82 (-2.06%)
PTC 25.47 Decreased By ▼ -1.15 (-4.32%)
SEARL 103.05 Decreased By ▼ -7.19 (-6.52%)
TELE 9.02 Decreased By ▼ -0.21 (-2.28%)
TOMCL 36.41 Decreased By ▼ -1.80 (-4.71%)
TPLP 13.75 Decreased By ▼ -0.02 (-0.15%)
TREET 25.12 Decreased By ▼ -1.33 (-5.03%)
TRG 58.04 Decreased By ▼ -2.50 (-4.13%)
UNITY 33.67 Decreased By ▼ -0.47 (-1.38%)
WTL 1.71 Decreased By ▼ -0.17 (-9.04%)
BR100 11,890 Decreased By -408.8 (-3.32%)
BR30 37,357 Decreased By -1520.9 (-3.91%)
KSE100 111,070 Decreased By -3790.4 (-3.3%)
KSE30 34,909 Decreased By -1287 (-3.56%)

BRUSSELS: EU chief Charles Michel defended Europe's much-criticised Covid-19 inoculation strategy on Tuesday by stressing Brussels will share jabs with the world and "will not use vaccines for propaganda purposes".

"We should not let ourselves be misled by China and Russia, both regimes with less desirable values than ours, as they organise highly limited but widely publicised operations to supply vaccines to others," the European Council president said.

The blunt comments came as the EU's 27 member states struggle to achieve lift-off with a plan to immunise 70 percent of adults by mid-September.

The start of it, over the first three months of this year, has been marked by severe criticism of Brussels for spearheading a collective purchase of vaccine doses that have largely failed to be delivered.

The strategy was backed by the member states and implemented by the European Commission.

Much of the initial delivery shortfall was down to Anglo-Swedish company AstraZeneca failing to meet its supply schedule to the European Union. Some member states, among them Hungary, the Czech Republic and Slovakia, are increasingly looking to vaccines not authorised by the EU's medicine regulator, the EMA, to fill the gap, in particular Russia's Sputnik V jab and ones from China.

The EMA is reviewing how effective and safe Sputnik V is, and an Italian-Swiss pharmaceutical company, Adienne, has agreed to produce it in Italy.

But the EU executive has indicated it is unwilling to add it to its vaccines portfolio, which is projected to deliver 2.6 billion doses over this year and next.

EU officials believe Russia and China are trying to score political points and expand influence by rushing to deliver their vaccines before they were rigorously vetted by regulators. Michel said the EU, in contrast, was "actively promoting its values" by investing early in Covid-19 vaccine development and being the prime driver of the Covax facility to deliver doses to poorer countries. "Without Europe, it would not have been possible to develop and produce several types of vaccines in less than one year," he said.

Michel also said that, while the European Union has a mechanism to monitor - and if necessary block - the export of doses out of the bloc, he was "shocked when I hear the accusations of 'vaccine nationalism' against the EU".

"The EU has never stopped exporting," he said, accusing Britain and the United States of banning the export of vaccines and vaccine components.

A British government spokesperson said: "The UK government has not blocked the export of a single COVID-19 vaccine. Any references to a UK export ban or any restrictions on vaccines are completely false."

Comments

Comments are closed.